Incidence of venous thromboembolism and the impact on survival in breast cancer patients

Journal of Clinical Oncology

Volumn 25, Issue 1, 2007, Pages 70-76

  Chew, Helen K ^a   Wun, Theodore ^a   Harvey, Danielle J ^a   Zhou, Hong ^a   White, Richard H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; BREAST TUMOR; DISEASE COURSE; METASTASIS; MIDDLE AGED; MORTALITY; REGISTER; RISK; THROMBOEMBOLISM; TIME; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS;

AGED; BREAST NEOPLASMS; CALIFORNIA; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM METASTASIS; REGISTRIES; RISK; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 34648864383     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.4393     Document Type: Article

References (31)

1. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
2. Clahsen PC, van de Velde CJ, Julien JP, et al: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 12:1266-1271, 1994
3. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
4. Pritchard KI, Paterson AH, Paul NA, et al: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer: National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737, 1996
5. Levine M, Hirsh J, Gent M, et al: Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889, 1994
6. Chew HK, Wun T, Harvey D, et al: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458-464, 2006
7. Alcalay A, Wun T, Khatri V, et al: Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol 24:1112-1118, 2006
8. White RH, Romano PS, Zhou H, et al: Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 158:1525-1531, 1998
9. White RH, Zhou H, Murin S, et al: Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93:298-305, 2005
10. California Department of Finance: E-4 Revised Historical City, County, and State Population Estimates, 1991-2000, with 1990 and 2000 Census Counts. Sacramento, CA, California Department of Finance, 2002
11. Elixhauser A, Steiner C, Harris DR, et al: Comorbidity measures for use with administrative data. Med Care 36:8-27, 1998
12. Stukenborg GJ, Wagner DP, Connors AF Jr: Comparison of the performance of two comorbidity measures, with and without information from prior hospitalizations. Med Care 39:727-739, 2001
13. Baum M, Budzar AV, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
14. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
15. Levitan N, Dowlati A, Remick SC, et al: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data. Medicine (Baltimore) 78:285-291, 1999
16. Blom JW, Doggen CJ, Osanto S, et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722, 2005
17. Stein PD, Beemath A, Meyers FA, et al: Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119:60-68, 2006
18. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
19. Rickles FR, Patierno S, Fernandez PM: Tissue factor, thrombin, and cancer. Chest 124:58S-68S, 2003 (suppl 3)
20. Haas S: Venous thromboembolism in medical patients: The scope of the problem. Semin Thromb Hemost 29:17-21, 2003 (suppl 1)
21. Alikhan R, Cohen AT, Combe S, et al: Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX study. Arch Intern Med 164:963-968, 2004
22. Gregg JP, Yamane AJ, Grody WW: Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 73:334-336, 1997
23. Sorensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000
24. Lee AY, Rickles FR, Julian JA, et al: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129, 2005
25. Kakkar AK, Levine MN, Kadziola Z, et al: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948, 2004
26. Klerk CP, Smorenburg SM, Otten HM, et al: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135, 2005
27. Petralia GA, Lemoine NR, Kakkar AK: Mechanisms of disease: The impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2:356-363, 2005
28. National Cancer Institute: Surveillance, Epidemiology and End Results. http://seer.cancer.gov
29. Newman LA, Griffith KA, Jatoi I, et al: Meta-analysis of survival in African American and white American patients with breast cancer: Ethnicity compared with socioeconomic status. J Clin Oncol 24:1342-1349, 2006
30. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996
31. Koopman MM, Prandoni P, Piovella F, et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: The Tasman Study Group. N Engl J Med 334:682-687, 1996